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Goldman J, Conley KA, Raehl A, Bondy DM, Pytowski B,
Swartz MA, Rutkowski JM, Jaroch DB, Ongstad EL. Regulation
of lymphatic capillary regeneration by interstitial flow in skin. Am J
Physiol Heart Circ Physiol 292: H2176–H2183, 2007. First published
January 12, 2007; doi:10.1152/ajpheart.01011.2006.—Decreased in-
terstitial flow (IF) in secondary lymphedema is coincident with poor
physiological lymphatic regeneration. However, both the existence
and direction of causality between IF and lymphangiogenesis remain
unclear. This is primarily because the role of IF and its importance
relative to the action of the prolymphangiogenic growth factor vas-
cular endothelial growth factor (VEGF)-C (which signals primarily
through its receptor VEGFR-3) are poorly understood. To clarify this,
we explored the cooperative roles of VEGFR-3 and IF in a mouse
model of lymphangiogenesis in regenerating skin. Specifically, a
region of lymphangiogenesis was created by substituting a portion of
mouse tail skin with a collagen gel within which lymphatic capillaries
completely regenerate over a period of 60 days. The relative impor-
tance of IF and VEGF-C signaling were evaluated by either inhibiting
VEGFR-3 signaling with antagonistic antibodies or by reducing IF. In
some cases, VEGF-C signaling was then increased with exogenous
protein. To clarify the role of IF, the distribution of endogenous
matrix metalloproteinases (MMPs) and VEGF-C within the regener-
ating region was determined. It was found that inhibition of either
VEGFR-3 or IF suppressed endogenous lymphangiogenesis. Reduc-
tion of IF was found to decrease lymphatic migration and transport of
endogenous MMP and VEGF-C through the regenerating region.
Therapeutic VEGF-C administration restored lymphangiogenesis fol-
lowing inhibition of VEGFR-3 but did not increase lymphangiogen-
esis following inhibition of IF. These results identify IF as an
important regulator of the pro-lymphangiogenic action of VEGF-C.
vascular endothelial growth factor receptor-3; endothelial cell
LYMPHATIC VESSELS DRAIN interstitial fluid and thereby guide
interstitial flow (IF; see Refs. 3 and 19). Although IF has been
identified as an important organizing factor in lymphangiogenesis
both in vivo and in vitro, its relationship to vascular endothelial
growth factor (VEGF)-C signaling has not been established. In
vivo, a model of lymphangiogenesis in regenerating mouse tail
skin demonstrated that the direction of IF (formed from lymph
that collected from upstream lymphatic capillaries and then
transported interstitially through the regenerating region) cor-
related with the formation of crude prelymphatic fluid chan-
nels, transport of matrix metalloproteinases (MMPs) and lym-
phatic growth factors, and ultimately the direction of lymphatic
endothelial cell (LEC) migration and organization (4, 15, 21).
In vitro, IF was shown to induce endothelial cell migration and
capillary morphogenesis (11) by skewing cell-secreted pro-
teases that liberate matrix-bound growth factors (7). Despite
such progress, a causal relationship between IF and lymph-
angiogenesis has not been demonstrated, primarily because it is
difficult to directly and selectively inhibit IF in a clearly
defined region of regenerating skin where lymphatic regrowth
can be observed over time. Furthermore, the ability of exoge-
nous VEGF-C to rescue lymphangiogenesis in tissues with
reduced IF is unclear.
In contrast to the lack of studies on IF in lymphangiogenesis,
numerous studies have been conducted to determine the role of
vascular growth factors and their receptors in lymphangiogen-
esis (20). It has recently been shown that excess VEGF-C can
augment lymphatic growth and function in adult tissues. For
example, lymphatic size, density, and function have been
reported to increase in skin when VEGF-C is overexpressed (5,
16–18, 24, 25) or delivered as recombinant protein (22). It is
now well accepted that VEGF-C activation of VEGF recep-
tor-3 (VEGFR-3) is necessary for lymphangiogenesis (1, 2, 9,
10, 12, 13, 24), and, in the same tail skin regeneration model,
blocking antibodies against VEGFR-3 prevented lymphangio-
genesis (13). Because of this, VEGF-C holds potential for
lymphangiogenic therapy in diseases of inadequate lymphatic
drainage. However, the relationship between VEGF-C/
VEGFR-3 signaling with IF during lymphangiogenesis is un-
known. For example, in the regenerating skin model, we
recently reported that excess VEGF-C induced hyperplasia of
regenerating lymphatics but was unable to increase lymphatic
migration or density above that of controls (6), possibly be-
cause IF is unaltered in both conditions. In another study,
VEGF-C-overexpressing transgenic mice were shown to have
incurred lymphatic hyperplasia in the tail skin without any
apparent changes to the density of the lymphatic network (9).
Thus, whereas the importance of VEGF-C in lymphangiogen-
esis is well established, the extent to which VEGF-C may, by
itself, promote new functional lymphatic growth and increase
IF in conditions of lymphedema remains debated.
Here we evaluate the ability of exogenous VEGF-C to
promote new lymphatic growth in a clearly defined region of
lymphatic-deficient skin using a previously characterized
model of mouse tail skin regeneration (4). In this model, a
circumferential section of tail skin is removed and replaced by
a collagen matrix within which skin regenerates in a relatively
scar-free manner. Lymphatic capillaries are not present in the
region initially, and IF is always directed from the distal
toward proximal regions of the tail (formed from lymph col-
lected by “upstream” lymphatics). We can induce lymphatic-
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free skin regeneration in the following two ways: 1) by em-
ploying VEGFR-3 neutralizing antibodies(13) or 2) by reduc-
ing IF. We then investigate the ability of exogenous VEGF-C
to promote lymphangiogenesis in both cases: in the first, where
IF is normal, vs. in the second, where IF is severely reduced,
as would be the case in chronic lymphedema. By testing the
ability of VEGF-C to augment lymphangiogenesis under each
conditions, we can clarify the extent to which lymphatic
growth depends on preexisting IF.
MATERIALS AND METHODS
Lymphangiogenesis model. A previously described model of lymph-
angiogenesis in regenerating tail skin of adult mice was used (4, 15,
21). For all studies, 6- to 8-wk-old female BALB/c mice (Charles
River Laboratories and Harlan) weighing 18–20 g were used; at least
four mice were examined for each condition at each time point. Mice
were anesthetized with a subcutaneous injection of ketamine (65
mg/kg), xylazine (13 mg/kg), and morphine (2 mg/kg). An analgesic,
butorphanol (0.05 mg/kg), was administered subcutaneously two
times daily for 3 days following the procedure. Protocols were
approved by the Animal Care and Use Committee of Michigan
Technological University and the Veterinary Authorities of the Can-
ton Vaud, Switzerland.
Regenerating regions were created in two ways. Either a 2-mm-
wide circumferential region (4) or a 2  2 mm square region (15) of
dermal tissue (containing the dermal lymphatic and blood capillary
networks) was excised midway up the tail, leaving the underlying
bone, muscle, major blood vessels, and tendons intact. The area was
then covered with a close-fitting, gas-permeable silicone sleeve and
filled with type I rat tail collagen (BD Pharmingen). The collagen
provides a well-controlled environment in which skin can regenerate;
thus, any LECs or lymphatic structures later observed within this
region are the result of newly initiated cell migration, proliferation,
and organization.
Experimental model 1: VEGFR-3 neutralization. For murine block-
ing studies, anti-mouse VEGFR-3 (mF4-31C1; see Ref. 13) was used
(Imclone Systems). In groups receiving mF4-31C1, a 2-mm circum-
ferential regenerating region was prepared as described above in the
lymphangiogenesis model section and 0.625 mg dose1 mouse1 of
the blocking antibody was administered postsurgery every 2 days by
intraperitoneal injection for a duration that varied by experimental
group. By employing this model, we can prepare a circumferential
region of regenerating skin with normal IF but without functional
VEGFR-3.
Experimental model 2: IF inhibition. IF through a regenerating
region of skin can be reduced by creating a square injury midway up
the tail. It has been recently shown that upstream lymph circumvents
this regenerated square region by flowing through the intact surround-
ing lymphatic network (15). By employing this model, we can reduce
IF through a regenerating square of skin.
Experimental model 3: IF inhibition. IF through the regenerating
mouse tail skin is formed from lymph that is collected from upstream
tissue (4, 6, 13). Therefore, IF through the regenerating region can be
reduced by surgical amputation of the upstream tissue. To reduce IF,
mice were anesthetized and fitted with a silicone sleeve to identify the
location for tail amputation. The tail was then completely severed
distal to the fitted sleeve, the sleeve was removed, and the tail end was
cauterized to prevent bleeding with special care undertaken to mini-
mize cautery-induced trauma. Mice were allowed to recover for 3 wk,
whereupon they were reanesthetized, and a regenerating region was
prepared as described above, with the modification that the regener-
ating region was placed at the edge of the severed tail instead of
midway up an intact tail (as was done in experimental model 1). By
employing this model, we can reduce IF through a regenerating
circumferential region of skin.
It should be noted that the surgical amputation process induces
injury-associated inflammation and wound healing, which may alter
local IF conditions. To monitor the degree of injury, the presence of
macrophages was assessed at the tip of the amputated tail 3 wk
subsequent to the amputation. Few macrophages, identified by the
F4/80 marker, were present at 3 wk at the amputated tail tip (data not
shown), suggesting that the 3-wk delay may have been sufficient for
natural wound healing processes to diminish in the tail skin.
VEGF-C therapy. To determine the ability of VEGF-C to augment
lymphangiogenesis in the absence of prior VEGFR-3 signaling or
under reduced IF, mouse tail skin regenerating regions were prepared
as described for experimental models 1 and 2. Mice with circumfer-
ential regenerating skin, as described in experimental model 1, re-
ceived mF4-31C1 for the first 10 days postsurgery. Mice with square
regenerating skin were created as described in experimental model 2.
At day 60 (at which time the skin and blood vasculature in both
models had completely regenerated but neither contained functional
lymphatics), mice in both groups (groups 1 and 2) received daily
injections of carrier-free recombinant human VEGF-C (R&D Sys-
tems) at the site of regenerated skin over a period of 15 days at 4
g dose1 mouse1 (12 l total volume/dose) for a total delivery of
60 g VEGF-C per mouse over this time period. Control mice
received saline injections (12 l total volume/dose) over this period of
time.
Detection of functional lymphatic capillaries via microlymphangiog-
raphy. To visualize lymph flow patterns in situ, a 1% solution of FITC
or tetramethylrhodamine-conjugated dextran of 7  104 Da dextran
(Molecular Probes/Invitrogen, Carlsbad, CA) was injected intrader-
mally in the tail end where it was taken up and transported by the
lymphatics in the proximal direction, revealing fluid channels and
functional lymphatic capillaries.
Immunofluorescence and immunohistochemistry. Tail specimens
were cut into either 10- or 60-m longitudinal cryosections and
immunostained. To detect LECs, a rabbit polyclonal antibody against
the lymphatic-specific hyaluronan receptor LYVE-1 (Upstate) was
used along with an Alexa Fluor 488 goat anti-rabbit secondary
antibody (Molecular Probes). LECs were defined as a cell nuclei
surrounded by LYVE-1 staining. To detect blood endothelial cells
(BECs), a biotinylated rat antimouse CD31 antibody (BD Pharmin-
gen) was used along with Alexa Fluor 555 streptavidin (Invitrogen).
BECs were defined as a cell nuclei surrounded completely by CD31
but not LYVE-1 staining (because LECs weakly express CD31). Cell
nuclei were labeled with 4,6-diamino-2-phenylindole (Vector Labo-
ratories). To determine the cell density, LECs and BECs in the
regenerating region were counted, and this number was divided by the
surface area of the region.
Biotinylated antibodies (R&D Systems) were used to detect
VEGF-C, MMP-2, MMP-3, and MMP-9 in 10-m longitudinal cryo-
sections. Antibody labeling was visualized with an avidin-biotin
complex-alkaline phosphatase kit and vector red substrate (Vector
Laboratories). Cell nuclei were counterstained with Gill’s hematoxy-
lin. Images were analyzed with Metamorph image analysis software
(Molecular Devices) to determine the percent coverage of positive
pixels in the regenerating region.
Statistical methods. At least three sections were counted per spec-
imen. Data are presented as means (SD). P values were calculated
using a two-tailed Student’s t-test.
RESULTS
Lymphangiogenesis is completely inhibited by transient
VEGFR-3 neutralization. Microlymphangiographies of mouse
tail skin at 60 days demonstrated regeneration of normal
hexagonal capillary architecture around the circumference of
regenerated skin in saline-treated control mice. However, nei-
ther normal architecture nor any apparent functional lymphatic
H2177VEGF-C AND INTERSTITIAL FLOW
AJP-Heart Circ Physiol • VOL 292 • MAY 2007 • www.ajpheart.org
 o
n
 O
ctober 29, 2010 
ajpheart.physiology.org
D
ow
nloaded from
 
capillaries had regenerated after 60 days in mice treated with
VEGFR-3 neutralizing antibodies for the 10, 17, or 25 days
following surgery (Fig. 1). In addition, immunostaining of
cryosections for LYVE-1 demonstrated that LECs were present
at day 60 throughout the regenerating region in saline-treated
controls but had failed to migrate in the regenerating region
when VEGFR-3 neutralizing antibodies were administered for
the first 25, 17, or 10 days following surgery (Fig. 1). Thus
even 10 days of VEGFR-3 blocking appeared to prevent
lymphatic regrowth in the regenerated skin. These results
confirmed earlier findings where VEGFR-3 blocking over the
entire 60-day period of regeneration was found to prevent
lymphatic capillary regrowth (13) and suggest that VEGFR-3
is active mainly in the early stages of lymphatic capillary
regeneration. These results also show that VEGFR-3 blocking
during the early stages of skin regeneration is sufficient to
generate chronic lymphatic deficiency in the fully regenerated
skin.
Exogenous VEGF-C augments lymphangiogenesis following
VEGFR-3 neutralization. It is well established that VEGF-C
can induce lymphatic capillary growth in normal mammalian
skin (2). To verify that exogenous VEGF-C could augment
lymphangiogenesis in a region of skin with normal IF that was
rendered chronically lymphatic-deficient by VEGFR-3 block-
ing, recombinant VEGF-C protein was administered to the regen-
erated region of mouse tail skin following systemic VEGFR-3
neutralization. To accomplish this, VEGFR-3 neutralizing anti-
bodies were administered systemically for the first 10 days of skin
regeneration, and no antibodies were delivered from day 10–60,
as before. Next, from day 60 to 75, VEGF-C protein was injected
in the tail skin at 4 g dose1 mouse1 day1. These VEGF-C
injections induced lymphatic growth, resulting in complete
rescue of lymphangiogenesis relative to normal regenerating
controls (Fig. 2, D and E ), whereas daily injections of saline
from day 60 to 75 did not improve lymphangiogenesis (Fig. 2,
B and E ). Thus exogenous VEGF-C can induce lymphangio-
genesis in lymphatic-free (regenerated) skin when IF is
present. This result allows us to compare the ability of
VEGF-C to promote lymphatic capillary growth in skin with
normal vs. reduced IF. Blood angiogenesis was unaffected by
either VEGFR-3 neutralization or VEGF-C therapy (Fig. 2, A
and C). It should be noted that neither surgical preparation of
the 2-mm skin injury nor VEGFR-3 neutralization resulted in
tail skin edema at any time during the period of experimental
observations.
Reduction of IF inhibits physiological and therapeutic
lymphangiogenesis. To clarify the role of IF in physiological
and therapeutic adult lymphangiogenesis, IF can be reduced in
the mouse tail. This can be accomplished by preparing regener-
ating square regions midway up the intact tail. Because the
lymphatic network that surrounds the regenerating square re-
gion remains intact, upstream lymph circumvents the square
regenerating region. Thus IF is demonstrably reduced in the
regenerating region of this model.
The square model of skin regeneration was employed to
investigate the ability of exogenously administered VEGF-C to
augment lymphangiogenesis in the presence of reduced IF.
Reduced IF and deficient lymphatic function were found in the
square region of control mice (Fig. 3A), in accordance with
previous findings (15). When 60-m-thick sections were la-
beled for the LYVE-1 marker, poorly organized and nonfunc-
tional individual LECs were found populating the center of the
regenerated square (Fig. 3B), confirming the role of IF in
physiological lymphatic regeneration. To determine whether
VEGF-C could augment lymphatic growth and function in this
reduced IF region, recombinant VEGF-C was administered
from day 60 to 75 postsurgery to the regenerated square region.
Fig. 1. Lymph fluid transport and lymphangiogenesis in regenerating skin.
Lymph fluid flows in the proximal direction, left to right. Dashed white lines
in the microlymphangiographies indicate location of the distal regenerating
region boundary. After surgery in saline-treated controls (60 days), functional
lymphatic capillaries with normal hexagonal lymphatic architecture have
reappeared in the regenerating region (A). Cryosections (10 m) were immu-
nostained against the lymphatic endothelial cell (LEC)-specific receptor
LYEV-1 (green), and cell nuclei were stained with DAPI (blue). LECs are
present throughout the regenerating region at 60 days, demonstrating complete
regeneration of lymphatics (B). After either 10, 17, or 25 days of anti-vascular
endothelial growth factor receptor (VEGFR)-3 administration, regeneration of
capillaries with normal hexagonal lymphatic architecture have been com-
pletely prevented (C, E, and G, respectively), when evaluated at day 60. Very
few LECs are present in their corresponding LYEV-1-stained sections (D, F,
and H), demonstrating effective inhibition of lymphangiogenesis. Bar in G 
1 mm. Bar in H  100 m. I: LEC density was determined from immuno-
stained cryosections of mouse tail skin at day 60 in normal controls and after
10, 17, or 25 days of VEGFR-3 neutralization. LEC densities and SD values
are presented normalized to the mean average control density.
H2178 VEGF-C AND INTERSTITIAL FLOW
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It was found that the regenerated square region was still
devoid of functional lymphatic capillaries, as demonstrated
by microlymphangiography (Fig. 3C). Following therapeutic
VEGF-C treatment, nonfunctional individual (i.e., unorga-
nized) LECs were found populating the center of the regener-
ated square (Fig. 3D), similar to controls. These results suggest
that IF may regulate the prolymphangiogenic action of
VEGF-C.
Reduction of IF inhibits lymphatic migration. At early times
in normal (nonamputated) regenerated tail skin, before lym-
phatics have regenerated, IF initially collects in the regenerat-
ing region from upstream lymphatics and moves through the
region interstitially in bulk flow patterns (4, 6). Over time,
upstream lymph that collects in the region moves interstitially
through discrete fluid channels that become populated with
LECs (4, 6). In the mouse tail, IF can be reduced through the
regenerating region by amputating tails midway up the tail and
preparing circumferential regenerating regions at the tail edge.
Because IF is formed from upstream lymph, which is generated
from upstream tissue, removal of upstream tissue in the am-
putated model reduces IF through the circumferential regener-
ating region.
It has recently been demonstrated that IF can generate
gradients of VEGF that direct endothelial cell migration and
tube formation in vitro (7). Based on these previous investiga-
tions, we hypothesized that reduced IF in skin might reduce
LEC migration and capillary formation by diminishing VEGF
transport and thereby decreasing VEGF gradients. The regen-
erating region of the circumferential injury model with reduced
IF is similar in geometry to the regenerating region of the
normal flow model. The similar geometry allows lymphatic
invasion and repopulation of the region to be compared be-
tween these models. Therefore, the circumferential reduced IF
model was employed to clarify the mechanism of reduced
VEGF-C effectiveness in low IF skin. It should be noted that,
whereas the square regenerated model allows IF reduction to
be directly demonstrated by microlymphangiography (and we
have used this model to correlate reduced IF with reduced
endogenous and exogenous lymphatic growth), it can be dif-
ficult to directly demonstrate IF reduction at the tip of an
Fig. 3. Lack of increased functional lymphatic growth following VEGF-C
therapy in a reduced interstitial flow (IF) model. A: microlymphangiography of
control skin (proximal direction is from right to left) shows functional lym-
phatic capillaries transporting lymph (red) around a regenerated square region
(yellow star), demonstrating both reduced IF and impaired functional lym-
phatic vessel regrowth in the square region of regenerated skin. B: 60-m
immunostained image from a mouse that received daily saline injections in a
regenerated square injury from day 60 to 75 postsurgery. Shown are fluores-
cence images with LYVE-1-positive LECs (green), lymph fluid tracer from
microlymphangiography (red), and DAPI-stained cell nuclei (blue) in the
regenerating square region. The yellow arrowhead indicates the center of the
regenerated square injury where multiple individual LECs are present, dem-
onstrating reduced lymphatic regrowth. Some lymph fluid tracer that was
below the detection threshold of the microlymphangiography can be seen in
the interstitial space in the image. This fluid tracer is not contained within the
lymphatics in the regenerating square but is contained within lymphatic
capillaries on the outer edge of the square region (indicated by white arrow),
confirming reduced lymphatic function in the low IF region. C: microlym-
phangiography from a mouse that received exogenous VEGF-C injections
shows flow of lymph (red) mostly around the regenerated square region
(yellow star), similar to control microlymphangiography. D: 60-m immuno-
stained image from a mouse that received daily VEGF-C injections in a
regenerated square injury from day 60 to 75 postsurgery. The yellow arrow-
head indicates the center of the regenerated square injury, and the white arrow
identifies a functional lymphatic vessel at the outer edge of the square region.
Multiple individual LECs are present in the square region in a manner similar
to the saline-treated controls; n  5 for each group. Bar  500 m in C and
100 m in D.
Fig. 2. Lymphangiogenesis following vascular endothelial growth factor
(VEGF)-C administration. Cryosections (60 m) were immunostained against
the LEC-specific receptor LYVE-1 (green) and the CD31 blood endothelial
cells (BEC) marker (red), and cell nuclei were stained with DAPI (blue).
Shown are fluorescence images of the regenerating region, with the proximal
direction from right to left. VEGFR-3 was neutralized for the first 10 days
postsurgery followed by saline injections from day 60 to day 75. LECs are not
present in the regenerating region at 60 days (B), although BECs are unaffected
by VEGFR-3 neutralization (A). Administration of VEGF-C protein from day
60 to 75 following VEGFR-3 neutralization from day 0 to 10 resulted in rescue
of lymphangiogenesis as shown by the presence of LECs throughout the
regenerating region (D), whereas BEC distribution is unaffected by this
treatment (C). E: LEC density was determined from immunostained 10-m
cryosections of mouse tail skin at the end point of each experimental condition
using an antibody against LYVE-1 and counting LYVE-1-positive cell nuclei
in the regenerating region. LEC densities and SDs are presented normalized to
the mean average control density; n  5 for normal regeneration and
VEGFR-3 neutralization, and n  4 for VEGF-C rescue. Bar  100 m.
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amputated mouse tail. However, the similar regenerating re-
gion geometries between the circumferential reduced IF and
normal IF models allow for a more direct comparison of
lymphatic migration than is possible with the regenerating
square model.
It was found that lymphatics filled the entire regenerating
region in normal flow controls after 25 days (Fig. 4B),
whereas few LECs were found in the regenerating region of
the reduced circumferential IF model at this time (Fig. 4D).
The presence of BECs appeared similar in each condition
(Fig. 4, A and C). Quantification of LEC density was
compared with normally regenerating control skin (Fig. 4E ).
This quantification confirmed our observations that reduced
IF conditions strongly inhibited lymphatic migration at this
time (P  0.005). This result provides evidence in support
of the hypothesis that IF may be important for directing LEC
migration.
Increased presence of VEGF-C and MMP in the absence of
IF. Interstitial transport of proteins is directed by lymphatic
drainage from the blood capillaries toward the lymphatic cap-
illaries in the form of IF. It has been hypothesized that
transport of MMPs by IF may be important for forming
prelymphatic fluid channels, along which LECs migrate during
the initial stages of lymphangiogenesis (4, 15). It has also been
hypothesized that transport of VEGF-C by IF and the genera-
tion of VEGF-C gradients may be important for directing the
migration of LECs (4, 7, 15). Because IF may generate growth
factor and protease gradients in regenerating skin, IF may be an
important regulator of the pro-lymphangiogenic activity of
MMPs and VEGF-C.
To directly demonstrate the importance of IF for the trans-
port of VEGF-C and MMPs, we examined the transient and
spatial distribution of VEGF-C, MMP-2, MMP-3, and MMP-9
via immunostaining of 10-m cryosections from circumferen-
tial models of normal and reduced flow dermis collected at day
10 (Fig. 5). VEGF-C, MMP-2, and MMP-3 were found to be
present in a diffuse pattern and at low levels in the control skin
but were concentrated at the distal portion of the deep dermis
and hypodermis of the reduced IF skin. MMP-9 was strongly
present throughout both normal-flow and reduced-flow regen-
erating dermis. Increases in the percent coverage in the regen-
erating region of VEGF-C, MMP-2, and MMP-3 were highly
significant relative to controls (P  0.005), whereas the mean
increase in MMP-9 coverage was not significantly different
from controls (Fig. 6), suggesting that MMP-9 distribution may
not be flow dependent. The increased presence of endogenous
VEGF-C in the reduced IF skin is particularly striking because
lymphangiogenesis was strongly inhibited by reduced IF.
These results demonstrate that lymphatic growth factors and
proteases collect in the subdermis of regenerating skin in the
absence of IF. Thus IF may be important for transporting
Fig. 4. Reduced lymphatic migration in low interstitial flow
model. Cryosections (60 m) were immunostained against the
LEC-specific receptor LYVE-1 (green) and the CD31 BEC
marker (red), and cell nuclei were stained with DAPI (blue).
Dashed white lines indicate the regenerating region. The prox-
imal direction is from right to left in all images. Blood (A) and
lymphatic (B) capillaries regenerated at day 25 in skin with
normal interstitial flow. Following inhibition of interstitial flow,
LECs are not found in the regenerating region at 25 days (D),
although BECs are unaffected (C), demonstrating specific inhi-
bition of lymphatic migration. E: LEC density was determined
from immunostained cryosections of mouse tail skin at the end
point of each experimental condition using an antibody against
LYVE-1. LEC densities and SDs are presented normalized to
the mean average control density; n  5 for each experimental
group. Bar  1 mm.
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growth factors and proteases during skin regeneration. These
results support the hypothesis that interstitial transport of
growth factors and proteases may be important for lymph-
angiogesis.
DISCUSSION
We demonstrate here that VEGF-C is able to rescue lymph-
angiogenesis in lymphatic-deficient skin when IF is present but
has a reduced ability to augment lymphangiogenesis when IF is
severely reduced. This may be because of the importance of
MMP and VEGF-C transport by IF for lymphangiogenesis. It
has been widely reported that excess VEGF-C can induce the
growth of new lymphatic capillaries in the adult (5, 16–18, 22,
24, 25). However, our results suggest that VEGF-C may have
a reduced ability to promote lymphatic growth in skin with
low IF. Our results confirm earlier findings that showed
lymphatic capillaries failed to organize in a modified version of
the mouse tail skin regeneration model in which a square
wound was created instead of a circumferential wound, allow-
ing lymph flow to circumvent the regenerating region (15).
It has been previously hypothesized that IF may promote
lymphatic migration by transporting VEGF-C and proteases
(4). Indeed, it has been reported in the same model of skin
regeneration that crude fluid channels, possibly generated from
soluble proteases transported by IF, precede lymphatic migra-
tion (4). The present study supports the notion that transport of
proteases and VEGF-C by IF may be important for the prolymph-
angiogenic action of VEGF-C. In further support of this notion,
we previously reported that excess VEGF-C does not enhance
the rate of LEC migration in regenerating skin or in vitro
through a proteolytically sensitive extracellular matrix (6). We
also found that VEGFR-3 neutralization prevents lymphatic
migration but does not prevent IF through the regenerating
region (13). In the present study, we have found that VEGF-C
has a significantly reduced ability to induce functional lymphatic
capillary organization when IF is reduced. Together, these find-
ings highlight the cooperative roles of IF and VEGF-C/VEGFR-3
signaling in lymphatic migration and functional organization.
In further support of our findings, it was recently found that
IF promoted blood and lymphatic capillary morphogenesis
Fig. 5. Increased VEGF-C and matrix metalloproteinase (MMP) presence in
low-flow-regenerating skin. Cryosections were immunostained against either
VEGF-C (A and B), MMP-2 (C and D), MMP-3 (E and F), or MMP-9 (G and
H) (red in each image) at day 10 in normally regenerating skin (column 1) or
reduced interstitial flow skin (column 2). The epidermis is located at the top of
each image. Shown is the distal half of the regenerating region under each
condition. VEGF-C, MMP-2, and MMP-3 are present at very low levels in the
control skin. However, VEGF-C and MMP-2 and -3 are seen pooling in the
deep dermis of the distal regenerating region of the reduced interstitial flow
skin (indicated by the yellow arrow). MMP-9 is strongly present throughout
both normal flow and reduced flow regenerating skin. Bar  100 m; n  5
for controls and for reduced interstitial flow.
Fig. 6. Quantification of VEGF-C and MMP coverage in low flow and
normally regenerating skin. Cryosections (10 m) obtained from skin follow-
ing 10 days of regeneration were immunostained against either VEGF-C,
MMP-2, MMP-3, or MMP-9. Presented as values normalized to controls, the
percent coverage of VEGF-C, MMP-2, and MMP-3 was found to be strongly
increased in the low-flow-regenerating skin relative to the normally regener-
ating control skin. The percent coverage of MMP-9 was not found to be
significantly increased in the low-flow-regenerating skin. All differences were
highly significant (P  0.005); n  4 for controls and n  5 for reduced
interstitial flow.
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in vitro (11). When bioavailability of VEGF was dependent
upon cell-secreted proteases (7), IF synergized with VEGF in
driving structure organization. It was hypothesized (and shown
computationally) that the slow IF skewed the pericellular
protease gradients, which in turn created amplified gradients of
liberated VEGF, leading to directed and enhanced cell-cell
communication and thus enhanced structure organization.
While these in vitro studies were missing many important
components of a wound healing environment, such as infiltrat-
ing immune cells and other sources of cytokines and growth
factors, they presented a novel mechanism that may help
explain how IF can work together with morphogenetic growth
factors to direct capillary organization. In the present study, we
have found that reduced IF diminishes VEGF-C and protease
gradients and causes decreased lymphatic migration and cap-
illary organization in vivo. These results support the hypothesis
that normal IF may generate gradients of morphogenetic
growth factors that direct LEC migration and capillary orga-
nization.
It is believed that excess VEGF-C expression by itself can
promote lymphangiogenesis and will be useful for lymph-
angiogenic therapy. Results from numerous investigations
have suggested that overexpression of one of the VEGFR-3
ligands, VEGF-C or VEGF-D, can generate an increased den-
sity of hyperplastic lymphatic capillaries that improve lym-
phatic function (5, 14, 23, 25), whereas other investigations
have reported that overexpression of VEGF-C may induce
lymphatic hyperplasia without increasing lymphatic density (6,
9, 24) and may also induce irregular lymphatic function (8).
These later results support our findings that increased VEGF-C
expression by itself may not necessarily lead to improved
lymphatic function.
Lymphatic flow in a mouse tail occurs in one direction,
allowing for a reduction in lymph volume and IF by amputa-
tion of the tail (which removes the source of upstream lymph)
or by creating a square injury, allowing lymph to circumvent
the region. By surgically preparing a region of regenerating
skin in this manner, we were able to create a permanent state
of lymphatic deficiency and poor IF. Thus the mouse tail, when
prepared in such a manner, may be useful for clarifying the role
of IF in lymphangiogenesis and for testing therapeutic strate-
gies to promote lymphatic regrowth in tissues with reduced IF.
We have used this model to correlate reduced transport of
VEGF-C and MMPs in skin with poor IF with reduced endog-
enous and therapeutic lymphangiogenesis.
In summary, our results are consistent with the substantial
literature demonstrating the necessity of VEGF-C/VEGFR-3
signaling for initiating lymphangiogenesis by inducing LEC
migration and proliferation. However, we have found a re-
duced ability of VEGF-C to increase lymphatic function in
tissue with poor IF by demonstrating that transport of VEGF-C
by IF may be important for the prolymphangiogenic activity of
VEGF-C.
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